KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sarepta Therapeutics (SRPT) Net Margin (2016 - 2025)

Historic Net Margin for Sarepta Therapeutics (SRPT) over the last 12 years, with Q2 2025 value amounting to 32.92%.

  • Sarepta Therapeutics' Net Margin rose 310500.0% to 32.92% in Q2 2025 from the same period last year, while for Sep 2025 it was 26.06%, marking a year-over-year increase of 185700.0%. This contributed to the annual value of 12.36% for FY2024, which is 554800.0% up from last year.
  • As of Q2 2025, Sarepta Therapeutics' Net Margin stood at 32.92%, which was up 310500.0% from 24.12% recorded in Q4 2024.
  • In the past 5 years, Sarepta Therapeutics' Net Margin registered a high of 32.92% during Q2 2025, and its lowest value of 203.85% during Q1 2023.
  • For the 5-year period, Sarepta Therapeutics' Net Margin averaged around 40.68%, with its median value being 25.42% (2021).
  • Its Net Margin has fluctuated over the past 5 years, first crashed by -1540300bps in 2023, then surged by 2126900bps in 2024.
  • Quarter analysis of 5 years shows Sarepta Therapeutics' Net Margin stood at 60.55% in 2021, then increased by 30bps to 42.51% in 2022, then surged by 127bps to 11.47% in 2023, then surged by 110bps to 24.12% in 2024, then soared by 37bps to 32.92% in 2025.
  • Its Net Margin stands at 32.92% for Q2 2025, versus 24.12% for Q4 2024 and 7.28% for Q3 2024.